VANDA PHARMACEUTICALS INC. Accounts Payable and Accrued Liabilities, Current
VANDA PHARMACEUTICALS INC. (VNDA) had Accounts Payable and Accrued Liabilities, Current of $69.99 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable and Accrued Liabilities, Current $69.99M.
- 2026-03-31: Accounts Payable and Accrued Liabilities, Current $60.62M.
- 2025-12-31: Accounts Payable and Accrued Liabilities, Current $68.30M.
- 2025-09-30: Accounts Payable and Accrued Liabilities, Current $47.62M.
| Period end | Accounts Payable and Accrued Liabilities, Current | Accounts Payable and Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $69.99M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $60.62M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $68.30M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $47.62M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $57.12M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $45.28M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $39.09M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $39.30M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $39.60M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $37.77M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $38.46M 10-K · filed 2025-02-14 | |
| 2023-09-30 | $32.59M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $31.93M 10-Q · filed 2023-07-28 | |
| 2023-03-31 | $35.09M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $45.55M 10-K · filed 2024-02-08 | |
| 2022-09-30 | $50.13M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $50.24M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $51.39M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $34.44M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $31.82M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $31.79M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $26.11M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $31.51M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $29.09M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $28.40M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $26.05M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $27.59M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $26.99M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $29.31M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $27.42M 10-Q · filed 2019-05-03 | |
| 2018-12-31 | $21.58M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $19.05M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $18.56M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $17.24M 10-Q · filed 2018-05-02 | |
| 2017-12-31 | $20.34M 10-K · filed 2019-02-19 | |
| 2017-09-30 | $18.92M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $19.13M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $18.02M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $16.20M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $17.57M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $17.93M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $22.66M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $15.77M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $45.89M 10-Q · filed 2015-11-04 | |
| 2014-12-31 | $7.29M 10-K · filed 2016-02-12 | $7.79M 10-Q · filed 2015-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |